Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines

被引：56

作者：

Anderson, Kenneth C. ^{[1
]}

Alsina, Melissa ^{[2
]}

Bensinger, William ^{[3
]}

Biermann, J. Sybil ^{[4
]}

Cohen, Adam D. ^{[5
]}

Devine, Steven ^{[6
]}

Djulbegovic, Benjamin ^{[2
]}

Faber, Edward A., Jr. ^{[7
]}

Gasparetto, Cristina ^{[8
]}

Hernandez-Illizaliturri, Francisco ^{[9
]}

Huff, Carol Ann

Kassim, Adetola ^{[10
]}

Krishnan, Amrita Y.

Liedtke, Michael ^{[11
]}

Meredith, Ruby ^{[12
]}

Raje, Noopur ^{[13
]}

Schriber, Jeffrey ^{[14
]}

Singhal, Seema ^{[15
]}

Somlo, George

Stockerl-Goldstein, Keith ^{[16
,17
]}

Treon, Steven P. ^{[1
]}

Weber, Donna ^{[14
]}

Yahalom, Joachim ^{[18
]}

Yunus, Furhan ^{[19
]}

Shead, Dorothy A.

Kumar, Rashmi

机构：

[1] Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Milford, MA USA

[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[3] Seattle Canc Care Alliance, Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[4] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA

[5] Fox Chase Canc Ctr, Philadelphia, PA USA

[6] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA

[7] Nebraska Med Ctr, UNMC Eppley Canc Ctr, Omaha, NE USA

[8] Duke Canc Inst, Durham, NC USA

[9] Roswell Pk Canc Inst, Buffalo, NY USA

[10] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[11] Stanford Canc Inst, Stanford, CA USA

[12] Univ Alabama, Birmingham Comprehens Canc Ctr, Tuscaloosa, AL 35487 USA

[13] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[14] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[15] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[16] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA

[17] Washington Univ, Sch Med, St Louis, MO 63130 USA

[18] Mem Sloan Kettering Canc Ctr, New York, NY USA

[19] Univ Tennessee, St Jude Childrens Res Hosp, Inst Canc, Knoxville, TN 37996 USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2013年 / 11卷 / 01期

关键词：

SINGLE-AGENT CARFILZOMIB; RANDOMIZED PHASE-III; PERIPHERAL NEUROPATHY; OPEN-LABEL; BORTEZOMIB; DEXAMETHASONE; COMBINATION; MANAGEMENT; ARM;

D O I：

10.6004/jnccn.2013.0004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

These NCCN Guidelines Insights highlight the important updates/changes specific to the management of relapsed or progressive disease in the 2013 version of the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma. These changes include the addition of new regimens as options for salvage therapy and strategies to mitigate the adverse effects and risks associated with newer regimens for the treatment of multiple myeloma. (JNCCN 2013;11:11-17)

引用

页码：11 / 17

页数：7

共 20 条

[1] Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events [J].

Arastu-Kapur, Shirin ;

Anderl, Janet L. ;

Kraus, Marianne ;

Parlati, Francesco ;

Shenk, Kevin D. ;

Lee, Susan J. ;

Muchamuel, Tony ;

Bennett, Mark K. ;

Driessen, Christoph ;

Ball, Andrew J. ;

Kirk, Christopher J. .

CLINICAL CANCER RESEARCH, 2011, 17 (09) :2734-2743

[2] Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma [J].

Arnulf, Bertrand ;

Pylypenko, Halyna ;

Groslcki, Sebastian ;

Karamanesht, Ievgenii ;

Leleu, Xavier ;

van de Velde, Helgi ;

Feng, Huaibao ;

Cakana, Andrew ;

Deraedt, William ;

Moreau, Philippe .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (12) :1925-1928

[3] Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma [J].

Badros, Ashraf ;

Burger, Angelika M. ;

Philip, Sunita ;

Niesvizky, Ruben ;

Kolla, Sarah S. ;

Goloubeva, Olga ;

Harris, Carolynn ;

Zwiebel, James ;

Wright, John J. ;

Espinoza-Delgado, Igor ;

Baer, Maria R. ;

Holleran, Julianne L. ;

Egorin, Merrill J. ;

Grant, Steven .

CLINICAL CANCER RESEARCH, 2009, 15 (16) :5250-5257

[4]

Dimopoulos MA, 2011, BLOOD, V118

[5] Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study [J].

Dimopoulos, Meletios A. ;

Mateos, Maria-Victoria ;

Richardson, Paul G. ;

Schlag, Rudolf ;

Khuageva, Nuriet K. ;

Shpilberg, Ofer ;

Kropff, Martin ;

Spicka, Ivan ;

Palumbo, Antonio ;

Wu, Ka Lung ;

Esseltine, Dixie-Lee ;

Liu, Kevin ;

Deraedt, William ;

Cakana, Andrew ;

van de Velde, Helgi ;

San Miguel, Jesus F. .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 86 (01) :23-31

[6] Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation [J].

Garderet, Laurent ;

Iacobelli, Simona ;

Moreau, Philippe ;

Dib, Mamoun ;

Lafon, Ingrid ;

Niederwieser, Dietger ;

Masszi, Tamas ;

Fontan, Jean ;

Michallet, Mauricette ;

Gratwohl, Alois ;

Milone, Giuseppe ;

Doyen, Chantal ;

Pegourie, Brigitte ;

Hajek, Roman ;

Casassus, Philippe ;

Kolb, Brigitte ;

Chaleteix, Carine ;

Hertenstein, Bernd ;

Onida, Francesco ;

Ludwig, Heinz ;

Ketterer, Nicolas ;

Koenecke, Christian ;

van Os, Marleen ;

Mohty, Mohamad ;

Cakana, Andrew ;

Gorin, Norbert Claude ;

de Witte, Theo ;

Harousseau, Jean Luc ;

Morris, Curly ;

Gahrton, Gosta .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (20) :2475-2482

[7]

Kirk CJ, 2008, BLOOD, V112, P954

[8] Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study [J].

Lentzsch, Suzanne ;

O'Sullivan, Amy ;

Kennedy, Ryan C. ;

Abbas, Mohammad ;

Dai, Lijun ;

Pregja, Silvana Lalo ;

Burt, Steve ;

Boyiadzis, Michael ;

Roodman, G. David ;

Mapara, Markus Y. ;

Agha, Mounzer ;

Waas, John ;

Shuai, Yongli ;

Normolle, Daniel ;

Zonder, Jeffrey A. .

BLOOD, 2012, 119 (20) :4608-4613

[9] Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study [J].

Moreau, Philippe ;

Pylypenko, Halyna ;

Grosicki, Sebastian ;

Karamanesht, Ievgenii ;

Leleu, Xavier ;

Grishunina, Maria ;

Rekhtman, Grigoriy ;

Masliak, Zvenyslava ;

Robak, Tadeusz ;

Shubina, Anna ;

Arnulf, Bertrand ;

Kropff, Martin ;

Cavet, James ;

Esseltine, Dixie-Lee ;

Feng, Huaibao ;

Girgis, Suzette ;

van de Velde, Helgi ;

Deraedt, William ;

Harousseau, Jean-Luc .

LANCET ONCOLOGY, 2011, 12 (05) :431-440

[10] Management of treatment-emergent peripheral neuropathy in multiple myeloma [J].

Richardson, P. G. ;

Delforge, M. ;

Beksac, M. ;

Wen, P. ;

Jongen, J. L. ;

Sezer, O. ;

Terpos, E. ;

Munshi, N. ;

Palumbo, A. ;

Rajkumar, S. V. ;

Harousseau, J. L. ;

Moreau, P. ;

Avet-Loiseau, H. ;

Lee, J. H. ;

Cavo, M. ;

Merlini, G. ;

Voorhees, P. ;

Chng, W. J. ;

Mazumder, A. ;

Usmani, S. ;

Einsele, H. ;

Comenzo, R. ;

Orlowski, R. ;

Vesole, D. ;

Lahuerta, J. J. ;

Niesvizky, R. ;

Siegel, D. ;

Mateos, M-V ;

Dimopoulos, M. ;

Lonial, S. ;

Jagannath, S. ;

Blade, J. ;

San Miguel, J. ;

Morgan, G. ;

Anderson, K. C. ;

Durie, B. G. M. ;

Sonneveld, P. .

LEUKEMIA, 2012, 26 (04) :595-608

← 1 2 →